Loading stock…

Tandem Diabetes Care, Inc. (TNDM) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated today

Tandem Diabetes Care, Inc.

TNDMMarket cap $1.09BPrice $15.7

Country🇺🇸United States

SectorHealthcare

IndustryHealthcare Equipment

Makes insulin pumps that automatically adjust doses for people with diabetes, using its touchscreen t:slim X2 platform. It's one of only a handful of companies competing in the fast-growing automated insulin delivery market.

In Bastion Portfolios?

52W Return+6%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+8%6

Revenue Forecast

Rev CAGR (1y)+6%4

Rev CAGR (3y)+10%7

Rev CAGR (5y)+10%7

Earnings Forecast

EPS Growth Y+1Loss1

EPS Growth Y+20%5

EPS Growth Y+3+637%10

Quality

Margins

EBIT Margin-4%1

Net Income Margin-6%1

Free Cash Flow Margin-3%2

Debt

Net Debt/EBITDAna–

Efficiency

ROE-48%1

ROA-6%1

Earnings Stabilityna–

GEAR+VERY WEAK5

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)na–

P/E Ratio (Forward 3y)203

P/BV8.42

EV Multiples

EV/EBITDA Fwd232

EV/EBIT Fwdna–

Yield

Free Cash Flow Yield-2.4%2

Dividend Yieldna–

Momentum

Short term

1 month return-18%1

3 month return+2%7

YTD return-29%2

Mid term

Price vs 52wHigh53%2

1 year return+6%5

Long term

3 year return-14%2

5 year return-88%1

Risk Shield

Price Risk

Beta0.67

Volatility74%1

Free Cash Flow

Free Cash Flow Margin-3%2

Free Cash Flow Yield-2.4%2

Quality

ROCE-6%1

Earnings Stabilityna–

Net Debt/EBITDAna–

02Growth

Is it actually growing, and how fast?

TNDMTandem Diabetes Care

Revenue FY25$1.0B

GROWTH RATING↗

AVERAGE59 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+8%6

Revenue, next 1Y+6%4

Revenue, next 3Y, CAGR+10%7

Revenue, next 5Y, CAGR+10%7

EARNINGS FORECAST▾SCORE

EPS growth, FY26ELoss1

EPS growth, FY27E0%5

EPS growth, FY28E+637%10

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 8%/yr over the last 3 years and is set to keep growing around 10%/yr.

The runway holds up: revenue is set to grow 10%/yr over five years.7/10

WATCH

A mid-pack grower, ahead of 59% of companies worldwide.

Revenue is set to grow 10%/yr over the next 3 years, a little ahead of the market.6/10

WEAKNESSES

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Top-Line Rocket

A middle-of-the-pack grower. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY WEAK14 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-18%1

3-month return+2%7

YTD return-29%2

MID & LONG-TERM▾SCORE

% of 52-week high53%2

1-year return+6%5

3-year return-14%2

5-year return-88%1

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over three months (+2%).

WATCH

None flagged.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-14% over three years and -88% over five), behind 80% of the market.

It's up 6% over the past year, but 47% below its 52-week high. That is a touch behind the market.

The stock is underperforming over the past month (-18%) and so far this year (-29%).

BOTTOM LINE

Weak Tape

Returns across short and long horizons rank poorly versus the market. Momentum offers no support here; the case has to come from other factors. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Tandem Diabetes Care, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

TNDMTandem Diabetes Care

Revenue FY25$1.0B

GROWTH RATING↗

AVERAGE59 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+8%6

Revenue, next 1Y+6%4

Revenue, next 3Y, CAGR+10%7

Revenue, next 5Y, CAGR+10%7

EARNINGS FORECAST▾SCORE

EPS growth, FY26ELoss1

EPS growth, FY27E0%5

EPS growth, FY28E+637%10

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 8%/yr over the last 3 years and is set to keep growing around 10%/yr.

The runway holds up: revenue is set to grow 10%/yr over five years.7/10

WATCH

A mid-pack grower, ahead of 59% of companies worldwide.

Revenue is set to grow 10%/yr over the next 3 years, a little ahead of the market.6/10

WEAKNESSES

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Top-Line Rocket

A middle-of-the-pack grower. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY WEAK14 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-18%1

3-month return+2%7

YTD return-29%2

MID & LONG-TERM▾SCORE

% of 52-week high53%2

1-year return+6%5

3-year return-14%2

5-year return-88%1

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over three months (+2%).

WATCH

None flagged.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-14% over three years and -88% over five), behind 80% of the market.

It's up 6% over the past year, but 47% below its 52-week high. That is a touch behind the market.

The stock is underperforming over the past month (-18%) and so far this year (-29%).

BOTTOM LINE

Weak Tape

Returns across short and long horizons rank poorly versus the market. Momentum offers no support here; the case has to come from other factors. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Tandem Diabetes Care, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community